ichorbio

Executive Summary

ichorbio is a UK-based biotechnology company founded in 2018 that specializes in the manufacturing of high-quality monoclonal antibodies for research and pre-clinical applications. The company focuses on producing critical in vivo-grade antibodies, including popular anti-mouse clones and human research-grade biosimilars, primarily serving the academic and pharmaceutical research sectors. Its core mission is to provide reliable, high-purity reagents essential for animal model studies and early-stage therapeutic discovery. By addressing the need for consistent, high-quality antibodies, ichorbio supports the reproducibility and reliability of preclinical research, a growing concern in the scientific community. Despite being a private company in the pre-clinical stage, ichorbio has established a presence in the competitive antibodies market by emphasizing quality and customer trust. The company's UK base and focus on research-grade products position it well for growth as the demand for reproducible research reagents increases. While financial details and specific growth metrics are not publicly available, ichorbio's niche in providing essential tools for drug discovery suggests steady demand. Future prospects may include expanding its product catalog, partnering with larger distributors, or developing novel biosimilars for emerging therapeutic targets.

Upcoming Catalysts (preview)

• Q4 2026Launch of new biosimilar antibody products for emerging targets60% success
• H1 2027Strategic partnership with academic consortia or large pharma for reagent supply50% success
• TBDExpansion of product line into novel in vivo-grade antibodies for immuno-oncology55% success